27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of the Dietary Approaches To Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid

      research-article
      , MD, PhD 1 , , MD, PhD 1 , , MD, DrPH 2 , , MD, MPH 1 , , MD, PhD 1
      Arthritis & rheumatology (Hoboken, N.J.)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Randomized trial data guiding dietary recommendations to lower serum uric acid (SUA), the etiologic precursor of gout, are scarce. We examined the effects of the DASH diet (a well-established diet that lowers blood pressure) and levels of sodium intake, on SUA.

          Methods

          We conducted an ancillary study of a randomized, crossover feeding trial in 103 adults with pre- or stage 1 hypertension. Participants were randomly assigned to receive either the DASH diet or a control diet (typical of the average American diet) and were further fed low, medium, and high sodium levels for 30 days each in random order. Body weight was kept constant. SUA was measured at baseline and following each feeding period.

          Results

          Trial participants were 55% women and 75% black with a mean age of 52 (SD, 10) years and mean SUA of 5.0 (SD, 1.3) mg/dL. The DASH diet reduced SUA by −0.35 mg/dL (95%CI: −0.65, −0.05; P=0.02) with a higher effect (−1.3 mg/dL; 95% CI −2.50, −0.08) among participants (N=8) with a baseline SUA ≥7 mg/dL. Increasing sodium intake from the low level, decreased SUA by −0.3 mg/dL (95%CI: −0.5, −0.2; P<0.001) during the medium sodium level and by −0.4 mg/dL (95%CI: −0.6, −0.3; P<0.001) during the high sodium level.

          Conclusions

          The DASH diet lowered SUA, and this effect was greater among participants with hyperuricemia. Moreover, we found that higher sodium intake decreased SUA, which enhances our knowledge of urate pathophysiology and risk factors of hyperuricemia.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

          Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. We randomly assigned 762 patients with gout and with serum urate concentrations of at least 8.0 mg per deciliter (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily for 52 weeks; 760 received the study drug. Prophylaxis against gout flares with naproxen or colchicine was provided during weeks 1 through 8. The primary end point was a serum urate concentration of less than 6.0 mg per deciliter (360 micromol per liter) at the last three monthly measurements. The secondary end points included reduction in the incidence of gout flares and in tophus area. The primary end point was reached in 53 percent of patients receiving 80 mg of febuxostat, 62 percent of those receiving 120 mg of febuxostat, and 21 percent of those receiving allopurinol (P<0.001 for the comparison of each febuxostat group with the allopurinol group). Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those receiving allopurinol (P=0.99 for 80 mg of febuxostat vs. allopurinol; P=0.23 for 120 mg of febuxostat vs. allopurinol). The median reduction in tophus area was 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg of febuxostat, as compared with 50 percent in those receiving allopurinol (P=0.08 for 80 mg of febuxostat vs. allopurinol; P=0.16 for 120 mg of febuxostat vs. allopurinol). More patients in the high-dose febuxostat group than in the allopurinol group (P=0.003) or the low-dose febuxostat group discontinued the study. Four of the 507 patients in the two febuxostat groups (0.8 percent) and none of the 253 patients in the allopurinol group died; all deaths were from causes that the investigators (while still blinded to treatment) judged to be unrelated to the study drugs (P=0.31 for the comparison between the combined febuxostat groups and the allopurinol group). Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate. Similar reductions in gout flares and tophus area occurred in all treatment groups. Copyright 2005 Massachusetts Medical Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Purine-rich foods, dairy and protein intake, and the risk of gout in men.

            Various purine-rich foods and high protein intake have long been thought to be risk factors for gout. Similarly, the possibility that the consumption of dairy products has a role in protecting against gout has been raised by metabolic studies. We prospectively investigated the association of these dietary factors with new cases of gout. Over a 12-year period, we prospectively examined the relationship between purported dietary risk factors and new cases of gout among 47,150 men who had no history of gout at base line. We used a supplementary questionnaire to ascertain whether participants met the American College of Rheumatology survey criteria for gout. Diet was assessed every four years by means of a food-frequency questionnaire. During the 12 years of the study, we documented 730 confirmed new cases of gout. The multivariate relative risk of gout among men in the highest quintile of meat intake, as compared with those in the lowest quintile, was 1.41 (95 percent confidence interval, 1.07 to 1.86; P for trend = 0.02), and the corresponding relative risk associated with seafood intake was 1.51 (95 percent confidence interval, 1.17 to 1.95; P for trend = 0.02). In contrast, the incidence of gout decreased with increasing intake of dairy products; the multivariate relative risk among men in the highest quintile, as compared with those in the lowest quintile, was 0.56 (95 percent confidence interval, 0.42 to 0.74; P for trend <0.001). The level of consumption of purine-rich vegetables and the total protein intake were not associated with an increased risk of gout. Higher levels of meat and seafood consumption are associated with an increased risk of gout, whereas a higher level of consumption of dairy products is associated with a decreased risk. Moderate intake of purine-rich vegetables or protein is not associated with an increased risk of gout. Copyright 2004 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Independent impact of gout on mortality and risk for coronary heart disease.

              Although gout and hyperuricemia are related to several conditions that are associated with reduced survival, no prospective data are available on the independent impact of gout on mortality. Furthermore, although many studies have suggested that hyperuricemia is associated with cardiovascular disease (CVD), limited data are available on the impact of gout on CVD. Over a 12-year period, we prospectively examined the relation between a history of gout and the risk of death and myocardial infarction in 51,297 male participants of the Health Professionals Follow-Up Study. During the 12 years of follow-up, we documented 5825 deaths from all causes, which included 2132 deaths from CVD and 1576 deaths from coronary heart disease (CHD). Compared with men without history of gout and CHD at baseline, the multivariate relative risks among men with history of gout were 1.28 (95% confidence interval [CI], 1.15 to 1.41) for total mortality, 1.38 (95% CI, 1.15 to 1.66) for CVD deaths, and 1.55 (95% CI, 1.24 to 1.93) for fatal CHD. The corresponding relative risks among men with preexisting CHD were 1.25 (95% CI, 1.09 to 1.45), 1.26 (95% CI, 1.07 to 1.50), and 1.24 (95% CI, 1.04 to 1.49), respectively. In addition, men with gout had a higher risk of nonfatal myocardial infarction than men without gout (multivariate relative risk, 1.59; 95% CI, 1.04 to 2.41). These prospective data indicate that men with gout have a higher risk of death from all causes. Among men without preexisting CHD, the increased mortality risk is primarily a result of an elevated risk of CVD death, particularly from CHD.
                Bookmark

                Author and article information

                Journal
                101623795
                42112
                Arthritis Rheumatol
                Arthritis & rheumatology (Hoboken, N.J.)
                2326-5191
                2326-5205
                23 February 2017
                December 2016
                01 December 2017
                : 68
                : 12
                : 3002-3009
                Affiliations
                [1 ]Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, and The Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore MD
                [2 ]Harvard Medical School, Gout and Crystal Arthropathy Center, and Massachusetts General Hospital, Boston MA
                Author notes
                Stephen P. Juraschek, M.D., Ph.D., Johns Hopkins Medical Institutions, 2024 East Monument Street, Suite 1-500, Baltimore, MD 21205, Phone: 410-502-6444, Fax: 410-502-6446, spj@ 123456jhmi.edu
                Article
                PMC5363397 PMC5363397 5363397 nihpa853970
                10.1002/art.39813
                5363397
                27523583
                9876cc06-232a-4b28-8aea-400a2f8377b6
                History
                Categories
                Article

                Comments

                Comment on this article